Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Which dialysis method works best for ICU kidney failure? a Head-to-Head test

NCT ID NCT06032884

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This trial compares two ways of filtering blood in critically ill patients with severe acute kidney injury: intermittent hemodialysis (done in sessions) and continuous renal replacement therapy (done non-stop). The goal is to see if the intermittent method is just as good as the continuous one in preventing death, lasting kidney damage, or the need for ongoing dialysis at 90 days. About 1,000 ICU adults on breathing support or blood pressure medication will be randomly assigned to one of the two methods. The study aims to help doctors choose the best dialysis approach for these very sick patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Two dialysis procedures: intermittent hemodialysis (IHD) and continuous renal replacement therapy (CRRT)
What this could lead to
If intermittent hemodialysis proves as effective as continuous therapy, it could offer a simpler, more flexible treatment option for ICU patients with severe kidney injury.
What could go wrong
The trial is large but still experimental; results may not show a clear difference, and both methods carry risks like low blood pressure or clotting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

554 people

The number who actually took part.

Started

Oct 2023

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adults (\> or= 18 years old) in ICU 2. Receiving (or who have received) invasive mechanical ventilation and/or catecholamine infusion 3. Availability of both equipment IHD and CRRT (in the investigational center at the time of inclusion) 4. One of the 2 following situations 4.a: Either at least one of the 3 following complications of AKI\* (whatever the KDIGO stage): persistent severe hyperkalaemia despite medical treatment, persistent severe metabolic acidosis despite medical treatment or severe pulmonary edema due to fluid overload despite diuretic therapy 4.b: Or an AKI stage 3 of KDIGO with one of the 2 following criteria: serum urea concentration\>40mmol/L or persistence of oligo-anuria\>3 days \*Definitions of these complication are provided in the main text (Section 7.1) 5. Affiliation of social security system 6. Written consent obtained from the patients (from a support person, family member or a close relative if the patient is not able to expressing and sign consent) or inclusion without initial consent in case of emergency, if the patient is not able to express his/her consent and in the absence of support person, family member or a close relative Exclusion Criteria: * Moribund state (patient likely to die within 24h) * Previous inclusion in the study * Subject deprived of freedom, or under a legal protective measure (example: patients under guardianship or curatorship) * Subject receiving state medical aid * Pregnancy or breastfeeding woman * Patient included in another research trial on AKI * Advanced chronic kidney disease (CKD) defined by an estimated GFR\<20 mL/min/1.73 m2 * Presence of a drug overdose or of a dialyzable toxin that necessitates RRT (because IHD may be preferable in these conditions). * Presence or clinical suspicion of renal obstruction, rapidly progressive glomerulonephritis, vasculitis, thrombotic microangiopathy or acute interstitial nephritis * Brain injured patients or other causes of increased intracranial pressure * Fulminant hepatic failure

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute kidney injury are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • c 001 Avicenne Service de réanimation médico chirurgicale

    Bobigny, Bobigny, 93000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.